Vanguard Group Inc. Has $95.02 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Vanguard Group Inc. cut its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,097,597 shares of the company's stock after selling 29,445 shares during the quarter. Vanguard Group Inc. owned about 4.66% of Apogee Therapeutics worth $95,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of APGE. Geode Capital Management LLC boosted its position in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock worth $48,401,000 after buying an additional 82,978 shares during the period. Barclays PLC boosted its position in Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company's stock worth $21,443,000 after acquiring an additional 287,243 shares during the period. Rhumbline Advisers grew its stake in shares of Apogee Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 52,720 shares of the company's stock worth $2,388,000 after purchasing an additional 1,750 shares in the last quarter. Swiss National Bank grew its stake in shares of Apogee Therapeutics by 17.5% in the fourth quarter. Swiss National Bank now owns 44,300 shares of the company's stock worth $2,007,000 after purchasing an additional 6,600 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Apogee Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company's stock valued at $1,736,000 after purchasing an additional 1,212 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Apogee Therapeutics Stock Down 0.5 %

Apogee Therapeutics stock traded down $0.17 during mid-day trading on Tuesday, hitting $33.11. The company's stock had a trading volume of 66,114 shares, compared to its average volume of 503,152. Apogee Therapeutics, Inc. has a twelve month low of $26.20 and a twelve month high of $63.50. The stock's fifty day moving average price is $35.65 and its two-hundred day moving average price is $44.00. The stock has a market capitalization of $1.49 billion, a P/E ratio of -13.70 and a beta of 1.72.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Equities analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on APGE shares. Citigroup initiated coverage on shares of Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics presently has an average rating of "Buy" and an average price target of $92.17.

Insiders Place Their Bets

In other news, CEO Michael Thomas Henderson sold 10,000 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at $38,983,558.05. This trade represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,970 shares of company stock worth $1,241,701 over the last ninety days. 36.10% of the stock is currently owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.